Envestnet Portfolio Solutions Inc. Sells 67,563 Shares of AstraZeneca PLC (NASDAQ:AZN)

Envestnet Portfolio Solutions Inc. lessened its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 46.0% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 79,206 shares of the company's stock after selling 67,563 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in AstraZeneca were worth $5,822,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Johnson Investment Counsel Inc. lifted its stake in AstraZeneca by 4.4% in the 1st quarter. Johnson Investment Counsel Inc. now owns 9,907 shares of the company's stock valued at $728,000 after purchasing an additional 414 shares during the last quarter. CWA Asset Management Group LLC acquired a new stake in shares of AstraZeneca in the first quarter valued at approximately $221,000. Essex Savings Bank lifted its position in shares of AstraZeneca by 3.4% in the first quarter. Essex Savings Bank now owns 5,772 shares of the company's stock valued at $424,000 after buying an additional 192 shares during the last quarter. Wolf Group Capital Advisors bought a new position in shares of AstraZeneca during the 1st quarter worth approximately $261,000. Finally, Clarius Group LLC increased its holdings in shares of AstraZeneca by 31.3% during the 1st quarter. Clarius Group LLC now owns 13,839 shares of the company's stock worth $1,017,000 after acquiring an additional 3,297 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

AZN traded down $0.81 during trading on Friday, hitting $69.95. The stock had a trading volume of 6,295,220 shares, compared to its average volume of 5,213,098. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70. The company has a 50 day moving average price of $70.34 and a 200-day moving average price of $70.42. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The firm has a market cap of $216.94 billion, a price-to-earnings ratio of 28.09, a P/E/G ratio of 1.28 and a beta of 0.38.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating the consensus estimate of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The business had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. During the same period in the prior year, the company posted $2.06 earnings per share. AstraZeneca's revenue was up 7.2% compared to the same quarter last year. As a group, research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.

Wall Street Analyst Weigh In

Separately, BNP Paribas began coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective for the company. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $85.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.